PanTheryx Technology

Biologics Pipeline

Pantheryx’ proprietary biologics platform enables us to develop novel therapeutics to address challenging disease states with significant unmet need.

Our R&D activities are focused on harnessing the synergistic effects of multiple bioactives, with the goal of developing first-in-class or best-in-class medicines. These medicines are being developed to address the underlying etiology of disease states, with the ability to target pathogens and support gut healing through their multi-bioactive backbone.

Our Biologics Pipeline


Pantheryx’ proprietary biologics platform enables us to develop novel therapeutics to address challenging disease states with significant unmet need.

Our R&D activities are focused on harnessing the synergistic effects of multiple bioactives, with the goal of developing first-in-class or best-in-class medicines. These medicines are being developed to address the underlying etiology of disease states, with the ability to target pathogens and support gut healing through their multi-bioactive backbone.

Active programs

Infectious disease

C. difficile infections

Infection with C. difficile (C. diff) is the most common cause of hospital-acquired diarrhea in the developed world. It was estimated to cause almost half a million infections in the United States in 2011, and 29,000 died within 30 days of the initial diagnosis. Of the major infectious diseases, diarrheal diseases were the only cause of mortality that increased nationally from 2000 to 2014: Many of those deaths can be attributed to C. diff.

Pantheryx is developing PTX-300 for the treatment of C. diff infections.

Gut dysregulation

Ulcerative Colitis and Crohn’s

The growth factors and repair factors of bovine colostrum provide an ideal bioactive backbone for health maintenance and gut repair in disease states such such as Ulcerative Colitis and Crohn’s. These factors begin to heal the gut through two stages: Cell migration, also called restitution, which starts in minutes, and through increased cell growth, called proliferation, which starts in 24-48 hours.

Pantheryx is developing PTX-400 for the treatment of Ulcerative Colitis and Crohn’s.

Drug-induced injury

Chemotherapy-induced diarrhea (CID)

Diarrhea is a well-recognized side effect associated with a variety of cancer treatments and chemotherapy agents, including fluorouracil (FU) and irinotecan (CPT-11). It’s been shown that grades 1 and 2 diarrhea may lead to an alteration in chemotherapy for 11% of patients, whereas approximately 45% of patients experiencing any-grade CID required dose reduction in chemotherapy. Because CID can result in significant morbidity and mortality, there is a large unmet need for the management, treatment and prevention of CID.

Pantheryx is developing PTX-500 for the treatment of CID.

Co-developing

Norovirus

About one out of every five cases of acute gastroenteritis that leads to diarrhea and vomiting is caused by norovirus. Causing 685 million cases of acute gastroenteritis each year, Norovirus is the most common cause of acute gastroenteritis worldwide. About 200 million cases are among children under 5, leading to an estimated 50,000 child deaths, mostly in developing countries. Every year norovirus is estimated to cost $60 billion worldwide due to healthcare costs and lost productivity.

PanTheryx is developing PTX-600, a biologic, for the treatment and prevention of norovirus infection.